The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 34, No. 5, pp. 580-584. DOI 10.1345/aph.19231
© 2000 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dever, L.
Right arrow Articles by Eng, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dever, L.
Right arrow Articles by Eng, R.

Research Articles

Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population

LL Dever, PA Oruwari, WE Figueroa, CA O'Donovan, and RH Eng

BACKGROUND: Hyperglycemia and new-onset diabetes mellitus have been reported to occur in HIV-infected patients treated with protease inhibitors. OBJECTIVE: To determine the effect of protease inhibitor therapy on serum glucose in a predominantly minority patient population. DESIGN: Retrospective record review. SETTING: Clinical HIV program of an urban Veterans Affairs medical center. PATIENTS: All HIV-infected patients receiving a protease inhibitor over a one-year period from September 1996 through August 1997. RESULTS: One hundred seventeen patients not previously known to be diabetic received protease inhibitors; seven (6%) developed symptomatic diabetes mellitus. Eight other patients had one or more serum glucose values >150 mg/dL. Mean random glucose values for patients who did not develop diabetes were higher during therapy than prior to initiation of protease inhibitors. CONCLUSIONS: Urban minority HIV-infected patients receiving combination antiretroviral therapy including a protease inhibitor may be at increased risk for the development of hyperglycemia and diabetes mellitus. Risk factors for diabetes mellitus should be identified and blood glucose monitored in all patients receiving protease inhibitors.


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Arch Intern Med, November 28, 2005; 165(21): 2541 - 2541.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
T. T. Brown, S. R. Cole, X. Li, L. A. Kingsley, F. J. Palella, S. A. Riddler, B. R. Visscher, J. B. Margolick, and A. S. Dobs
Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
Arch Intern Med, May 23, 2005; 165(10): 1179 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Chen, A. Misra, and A. Garg
Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4845 - 4856.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2000 by Harvey Whitney Books Company.